Kanamycin
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Kanamycin: From Bacterial Infections to Hyperamylasemia
One-Sentence Summary
Kanamycin is an aminoglycoside antibiotic historically used to treat serious gram-negative bacterial infections and as a second-line agent for tuberculosis. The TxGNN model predicts it may be effective for Hyperamylasemia (ranked #1 among 10 predicted indications), however, no clinical trials or publications currently support this direction. Evidence sits at Level L5 — model prediction only — and the proposed mechanistic link reflects an adverse effect rather than a therapeutic pathway.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Gram-negative bacterial infections (aminoglycoside antibiotic; no Singapore registration on record) |
| Predicted New Indication | Hyperamylasemia |
| TxGNN Prediction Score | 94.53% |
| Evidence Level | L5 |
| Singapore Market Status | ✗ Not marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for Kanamycin in this evidence pack. Based on known pharmacology, Kanamycin is an aminoglycoside antibiotic that inhibits bacterial protein synthesis by irreversibly binding to the 30S ribosomal subunit, causing misreading of mRNA and disruption of the translocation step — ultimately leading to bacterial cell death. This mechanism is entirely antibacterial in nature.
Hyperamylasemia (elevated serum amylase) typically arises as a secondary phenomenon from acute pancreatitis, salivary gland disease, or renal impairment. The only conceivable link between Kanamycin and hyperamylasemia is that Kanamycin's well-documented nephrotoxicity could theoretically impair glomerular filtration, reducing amylase clearance and causing serum levels to rise. This, however, represents a potential adverse effect pathway — Kanamycin would precipitate hyperamylasemia as a complication, not resolve it therapeutically.
There is no plausible mechanistic rationale for using Kanamycin to treat elevated amylase. It is worth noting that among the 10 TxGNN-predicted indications for this drug, gonococcal urethritis (rank #5, Evidence Level L3, 20 publications spanning 1958–2018) and uterine inflammatory disease / pelvic inflammatory disease (rank #8, Evidence Level L3, 2 clinical trials + 4 publications) carry substantially more credible biological rationale and clinical historical data as repurposing candidates.
Clinical Trial Evidence
Currently no related clinical trials registered for Hyperamylasemia.
Literature Evidence
Currently no related literature available for Hyperamylasemia.
Singapore Market Information
Kanamycin is currently not registered in Singapore. No product licences are on record, and the drug has no documented market presence.
Safety Considerations
Please refer to the package insert for safety information.
Note for reviewers: Safety data (key warnings, contraindications, drug–drug interactions) were not retrievable for this evidence pack. Based on general pharmacological knowledge, Kanamycin is an aminoglycoside antibiotic associated with nephrotoxicity and ototoxicity; these risks would be particularly relevant to any clinical evaluation.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked TxGNN prediction (hyperamylasemia, score 94.53%) is supported only by computational modelling — no clinical trials or literature exist for this indication, and the mechanistic rationale describes an adverse effect of the drug rather than a therapeutic one, making this indication unsuitable for repurposing development.
To proceed with any repurposing evaluation, the following is needed:
- Redirect focus to higher-evidence predictions: Gonococcal urethritis (rank #5, L3, 20 publications, including comparative RCT-like studies from 1958–2018) and uterine inflammatory disease / PID (rank #8, L3, 2 completed clinical trials + 4 publications) represent far more plausible repurposing candidates with established mechanistic rationale
- Obtain full safety profile: Retrieve TFDA/HSA package insert to document warnings, contraindications, and nephrotoxicity/ototoxicity thresholds before any clinical evaluation
- Clarify regulatory status: Confirm whether Kanamycin can be imported or compounded in Singapore given zero current registrations
- Resistance landscape review: Assess contemporary antimicrobial susceptibility data before pursuing any infectious disease indication, as resistance trends (particularly in N. gonorrhoeae) have shifted significantly since the bulk of the supporting literature was published
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.